PROCEPT BioRobotics (PROCEPT BioRobotics) Risk Assessment

View and export this data going back to 2021. Start your Free Trial

What is PROCEPT BioRobotics Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of PROCEPT BioRobotics is: No Data: Cannot be evaluated.

Competitive Comparison of PROCEPT BioRobotics's Risk Assessment

For the Medical Devices subindustry, PROCEPT BioRobotics's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PROCEPT BioRobotics's Risk Assessment Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, PROCEPT BioRobotics's Risk Assessment distribution charts can be found below:

* The bar in red indicates where PROCEPT BioRobotics's Risk Assessment falls into.

PROCEPT BioRobotics (NAS:PRCT) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

PROCEPT BioRobotics Risk Assessment Related Terms

Thank you for viewing the detailed overview of PROCEPT BioRobotics's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

PROCEPT BioRobotics (PROCEPT BioRobotics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » PROCEPT BioRobotics Corp (NAS:PRCT) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

900 Island Drive, Redwood, CA, USA, 94065

Website

https://www.procept-biorobotics.com

PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. The company's assets are based in the United States. Its revenue is generated from sales of the AquaBeam Robotic System and the accompanying single-use disposable handpieces.

Executives

Alaleh Nouri	officer: SVP, GEN COUNSEL, CORP. SEC.	1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Kevin Waters	officer: Senior VP, CFO	1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Frederic H Moll	director	C/O INTUITIVE SURGICAL INC, 950 KIFER ROAD, SUNNYVALE CA 94086
Wood Morgan Colby	director	C/O PROCEPT BIOROBOTICS CORPORATION, 900 ISLAND DRIVE, REDWOOD CA 94065
Reza Zadno	director, officer: President, CEO	2710 SAND HILL ROAD, SUITE 200, MENLO PARK CA 94025
Hisham Shiblaq	officer: SVP, Commercial Operations	C/O PROCEPT BIOROBOTICS CORPORATION, 900 ISLAND DRIVE, REDWOOD CITY CA 94065
Thomas M Krummel	director	C/O CALIFORNIA WATER SERVICE GROUP, 1720 N. FIRST STREET, SAN JOSE CA 95118
Viking Global Investors Lp	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Parent Gp Llc	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Dragsa 88 Llc	10 percent owner	55 RAILROAD AVE, GREENWICH CT 06830
Rose Sharon Shabet	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Illiquid Investments Sub-master Lp	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Gp Llc	10 percent owner	55 RAILROAD AVENUE, GREENWICH CT 06830
Viking Global Opportunities Portfolio Gp Llc	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
David C. Ott	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901